Compare

Alcon Inc./Fr. ALC

1D1W1M3M6MYTD1Y5YMAX

About Alcon Inc.

Alcon Inc. is a global company specializing in eye care products and medical devices, serving the healthcare sector. The company focuses on two main divisions: Surgical and Vision Care. Its Surgical segment offers ophthalmic products such as cataract, retinal, and refractive surgery equipment, while the Vision Care segment provides contact lenses and lens care products. Headquartered in Geneva, Switzerland, Alcon was founded in 1945 as a small ophthalmic shop in Texas and has since expanded its footprint internationally. Alcon benefits from its extensive research and development capabilities, underpinned by a robust portfolio of market-driven innovations aiming to address unmet eye care needs globally.
Ticker
Fr. ALC
Sector
Health
Primary listing
XSWX
Employees
25,000
Headquarters
Geneva, Switzerland
Website
www.alcon.com

Alcon Inc. Metrics

BasicAdvanced
CHF 28B
54.45
CHF 1.08
0.70
CHF 0.28
0.48%

What the Analysts think about Alcon Inc.

Analyst ratings (Buy, Hold, Sell) for Alcon Inc. stock.
Analyst projections of the future price of Alcon Inc. stock.

Bulls say / Bears say

Q2 sales rose 7% at constant currency across Surgical and Vision Care. Alcon kept its 5–7% full-year sales growth target and raised its core EPS growth outlook to 12–15%, signalling continued demand and improving earnings momentum. (Alcon)
UNITY-driven equipment sales grew 25% at constant currency to $279 million in Q2, and Alcon has begun commercialising the Unity M microscope. A successful rollout could extend growth from the new surgical platform. (Alcon, Healio)
Core gross margin widened 250 basis points to 64.7% in Q2, and first-half free cash flow reached $693 million. Although the margin also benefited from a $15 million licensing item, cash generation supported $538 million of shareholder returns. (Alcon, The Motley Fool)
Implantables grew only 1% in Q2 as US cataract procedure volumes stayed flat and competition weighed on intraocular lenses. That makes it harder for Alcon to turn demand for premium lenses into stronger surgical sales. (Alcon, Simply Wall St)
Alcon expects tariffs to add $40–90 million to 2026 costs after mitigation and refunds, with US import rates of about 10–12.5%. This remains a drag on margins, while roughly two-thirds of the expected $60 million refund is intended for reinvestment. (Alcon)
Alcon discontinued its PowerVision accommodating-lens programme, and a US$453 million one-off loss left Q2 reported diluted EPS at $0.00 despite core EPS of $0.84. The write-off highlights the financial and development risks behind its innovation pipeline. (Simply Wall St, Alcon)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.

Alcon Inc. Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Alcon Inc. Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Alcon Inc.

AllEURUSDGBP
Funds
Fund name
Fund size
Fr. ALC weighting
iShares MSCI Europe Health Care Sector€ESIH
€890M1.79%
iShares MSCI Europe Health Care Sector£ESIH
€890M1.79%
iShares STOXX Europe 600 Health Care€EXV4
€709M1.76%
iShares MSCI Europe SRI£IESG
€3.2B1.29%
iShares MSCI Europe SRI€IESE
€3.2B1.29%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.